Compare Apollo Global Management Ord Shs (APO) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Cassava Sciences Inc — how do they compare? Apollo Global Management Ord Shs trades at $140.17 (market cap $76.04B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Apollo Global Management Ord Shs is far larger — about 1592.5× Cassava Sciences Inc's market cap, and Apollo Global Management Ord Shs pays a 1.7% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| APO | FLNA | |
|---|---|---|
Market Cap | $76.04B | $47.75M |
Sector | Financials | Health |
52-Week High | $152.70 | $4.64 |
52-Week Low | $100.30 | $0.87 |
Enterprise Value | -$175.45B | -$34.93M |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $127.44, down 0.43% today but maintains a bullish technical outlook with strong analyst support. The company reported mixed Q2 2026 results with an EPS miss but record $60 billion quarterly inflows, driving AUM to $1.05 trillion. Valuation metrics show a P/E of 45.35 and P/S of 2.11, with solid profitability margins and consistent dividend payments.
APO presents a compelling investment case with strong institutional backing and growth in fee-related earnings, though elevated P/E and recent earnings miss warrant caution. The consensus price target of $151.50 suggests 19% upside potential, supported by the company's leadership in private credit and AI infrastructure expansion initiatives.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
